Company:Shenzhen Kangtai Biological Products
From HandWiki
Short description: Chinese biopharmaceutical company
[ ⚑ ] 22°32′48″N 113°56′37″E / 22.5467°N 113.9437°E
| Type | Public |
|---|---|
| SZSE: 300601 | |
| Founded | September 8, 1992 |
| Founder | Du Weimin[1] |
| Headquarters | 6 Kefa Road, Science and Technology Park, Nanshan District, Shenzhen, Shenzhen , China |
Number of employees | 2043[2] |
| Website | en |
Shenzhen Kangtai Biological Products (Chinese: 深圳康泰生物制品股份有限公司, SZSE: 300601), also known as BioKangtai (Chinese: 康泰生物), is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.[2]
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China.[3][4][1]
References
- ↑ 1.0 1.1 "Scandal Dogs AstraZeneca's Vaccine Partner in China". The New York Times. 7 January 2021. https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html.
- ↑ 2.0 2.1 "Shenzhen Kangtai Biological Products Co Ltd". Bloomberg. https://www.bloomberg.com/profile/company/SKBZ:CH.
- ↑ "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. 14 May 2021. https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai-idUSKBN2CV1F6.
- ↑ "AstraZeneca's China partner expects to be able to make 400 million COVID-19 vaccine doses a year". Reuters. 2 February 2021. https://www.reuters.com/article/us-health-coronavirus-kangtai-astrazenec-idUSKBN2A20VB.
 |
